Pimurutamab Market Summary

Key Factors Driving Pimurutamab Growth

1. Differentiated anti-EGFR antibody with improved pharmacokinetic profile

Pimurutamab is a next-generation humanized anti-EGFR monoclonal antibody engineered to exhibit reduced immunogenicity, enhanced EGFR-binding affinity, and an extended half-life through Fc engineering. The prolonged half-life enables once every 3-week dosing, making it more convenient for combination therapy with immune checkpoint inhibitors and chemotherapy than conventional weekly EGFR antibodies. This differentiated profile could improve treatment compliance and clinical utility if confirmed in late-stage studies.

2. Large Phase II/III program in first-line squamous NSCLC targets a substantial market

Henlius has initiated an international randomized Phase II/III trial evaluating pimurutamab plus serplulimab (anti-PD-1) and chemotherapy as first-line treatment for advanced squamous NSCLC. The study compares the regimen against placebo combined with serplulimab or pembrolizumab plus chemotherapy. Squamous NSCLC accounts for approximately 25–30% of all NSCLC cases, representing a major global oncology market. Positive outcomes in this pivotal program could support regulatory submissions in multiple regions.

3. Encouraging early clinical data support continued development

Henlius previously reported that the Phase Ib/II study of pimurutamab combined with chemotherapy demonstrated that the regimen was safe and well tolerated, providing the clinical rationale for advancing into pivotal studies. The favorable safety profile is particularly important for combination regimens involving PD-1 inhibitors, where maintaining tolerability while improving efficacy is essential for widespread clinical adoption.

4. Global clinical expansion reduces regulatory risk and broadens commercialization opportunities

Development has expanded beyond China into an international multicenter program. During 2026, the Phase II/III study received regulatory clearance in Australia, while the first patient was dosed in China, marking the transition to global clinical execution. International development increases the likelihood of future regulatory filings across multiple markets and strengthens the product's commercial potential if pivotal efficacy is demonstrated.

5. Multiple combination strategies expand lifecycle potential

Beyond first-line sqNSCLC, Henlius is evaluating pimurutamab in additional immuno-oncology combinations. The company has initiated an international Phase II/III trial evaluating HLX43 (anti-PD-L1 antibody-drug conjugate) as monotherapy or in combination with pimurutamab versus docetaxel in previously treated advanced/metastatic squamous NSCLC. These studies create opportunities for lifecycle expansion across different treatment lines and combination regimens, increasing the long-term addressable market.

6. Commercial outlook: High potential but no validated sales forecast available

Pimurutamab remains a clinical-stage asset with no commercial revenue, and Henlius has not issued product-specific revenue guidance or long-term sales projections. Its commercial opportunity will depend on successful completion of the ongoing international Phase II/III trials, regulatory approvals, reimbursement decisions, and its ability to demonstrate clinically meaningful benefit over established PD-1–chemotherapy regimens. Given the absence of company guidance and the product's pre-commercial status, any quantitative sales forecast would be speculative and is not supported by verified company disclosures or peer-reviewed literature.

Pimurutamab Recent Developments

In April 2026, Henlius announced that a randomized, double-blind, multicentre, parallel-controlled Phase II/III clinical trial evaluating its self-developed recombinant anti-EGFR mAb pimurutamab (HLX07) in combination with the anti-PD-1 mAb serplulimab (trade name: Hetronifly in Europe) and chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (sqNSCLC) has completed Clinical Trial Notification (CTN) in Australia, marking a crucial step in exploring innovative treatments for first-line treatment of sqNSCLC.

“Pimurutamab Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Pimurutamab for potential indication like Non-small cell lung cancer, Gastric cancer, Nasopharyngeal cancer, Oesophageal cancer, Rectal cancer, Squamous cell cancer, Colorectal cancer, and Solid tumours in the 7MM. A detailed picture of Pimurutamab’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Pimurutamab for potential indications. The Pimurutamab market report provides insights about Pimurutamab’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Pimurutamab performance, future market assessments inclusive of the Pimurutamab market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Pimurutamab sales forecasts, along with factors driving its market.

Pimurutamab Drug Summary

Pimurutamab is an investigational glycoengineered, humanized IgG1 monoclonal antibody developed by Shanghai Henlius Biotech for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors. Designed as a next-generation ("biobetter") version of cetuximab, pimurutamab selectively binds to the extracellular domain of EGFR, blocking ligand-induced receptor activation and dimerization, thereby inhibiting downstream signaling pathways involved in tumor cell proliferation, survival, angiogenesis, and metastasis. Its glycoengineered Fc region enhances antibody-dependent cell-mediated cytotoxicity (ADCC), potentially providing greater antitumor activity than first-generation anti-EGFR antibodies. Administered by intravenous infusion, pimurutamab is being evaluated in clinical trials, both as monotherapy and in combination with other anticancer agents, for patients with EGFR-positive malignancies such as squamous cell carcinoma of the head and neck and other advanced solid tumors. Early clinical studies have demonstrated encouraging antitumor activity, a manageable safety profile, and pharmacokinetic characteristics supportive of further clinical development as a targeted immunotherapy for EGFR-driven cancers. The report provides Pimurutamab’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Pimurutamab Market Report

The report provides insights into:

• A comprehensive product overview including the Pimurutamab MoA, description, dosage and administration, research and development activities in potential indication like Non-small cell lung cancer, Gastric cancer, Nasopharyngeal cancer, Oesophageal cancer, Rectal cancer, Squamous cell cancer, Colorectal cancer, and Solid tumours.
• Elaborated details on Pimurutamab regulatory milestones and other development activities have been provided in Pimurutamab market report.
• The report also highlights Pimurutamab‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Pimurutamab market report also covers the patents information, generic entry and impact on cost cut.
• The Pimurutamab market report contains current and forecasted Pimurutamab sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Pimurutamab market report also features the SWOT analysis with analyst views for Pimurutamab in potential indications.

Methodology

The Pimurutamab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pimurutamab Analytical Perspective by DelveInsight

• In-depth Pimurutamab Market Assessment

This Pimurutamab sales market forecast report provides a detailed market assessment of Pimurutamab for potential indication like Non-small cell lung cancer, Gastric cancer, Nasopharyngeal cancer, Oesophageal cancer, Rectal cancer, Squamous cell cancer, Colorectal cancer, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Pimurutamab sales data uptil 2034.

• Pimurutamab Clinical Assessment

The Pimurutamab market report provides the clinical trials information of Pimurutamab for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Pimurutamab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Pimurutamab Market Potential & Revenue Forecast

• Projected market size for the Pimurutamab and its key indications
• Estimated Pimurutamab sales potential (Pimurutamab peak sales forecasts)
• Pimurutamab Pricing strategies and reimbursement landscape

Pimurutamab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Pimurutamab Market positioning compared to existing treatments
• Pimurutamab Strengths & weaknesses relative to competitors

Pimurutamab Regulatory & Commercial Milestones

• Pimurutamab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Pimurutamab Clinical Differentiation

• Pimurutamab Efficacy & safety advantages over existing drugs
• Pimurutamab Unique selling points

Pimurutamab Market Report Highlights

• In the coming years, the Pimurutamab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Pimurutamab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pimurutamab’s dominance.
• Other emerging products for Non-small cell lung cancer, Gastric cancer, Nasopharyngeal cancer, Oesophageal cancer, Rectal cancer, Squamous cell cancer, Colorectal cancer, and Solid tumours are expected to give tough market competition to Pimurutamab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pimurutamab in potential indications.
• Analyse Pimurutamab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Pimurutamab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Pimurutamab in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Pimurutamab? How strong is Pimurutamab’s clinical and commercial performance?
• What is Pimurutamab’s clinical trial status in each individual indications such as Non-small cell lung cancer, Gastric cancer, Nasopharyngeal cancer, Oesophageal cancer, Rectal cancer, Squamous cell cancer, Colorectal cancer, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pimurutamab Manufacturers?
• What are the key designations that have been granted to Pimurutamab for potential indications? How are they going to impact Pimurutamab’s penetration in various geographies?
• What is the current and forecasted Pimurutamab market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Pimurutamab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Pimurutamab for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Pimurutamab? What is the duration of therapy and what are the geographical variations in cost per patient?